Seronegative myasthenic crisis: a multicenter analysis

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Myasthenic crisis (MC) is a severe, life-threatening exacerbation in myasthenia gravis (MG) patients.
• Seronegative MG accounts for 10-15% of all MG cases, yet outcomes during MC are understudied.
• Understanding seronegative MC is crucial for comprehensive MG management.

Purpose of the Study:

• To compare the clinical characteristics and outcomes of myasthenic crisis in seronegative MG versus acetylcholine-receptor-antibody-positive MG (AChR-MG).
• To analyze differences in patient demographics, disease course, and treatment response between the two groups.

Main Methods:

• Retrospective multicenter study in Germany (2006-2015).
• Subgroup analysis of patients experiencing MC, comparing seronegative MG (n=15) with AChR-MG (n=142).
• Data collected on demographics, disease duration, thymus status, and critical care parameters.

Main Results:

• Seronegative MC patients were younger (54.3 vs. 66.5 years) and had a higher rate of thymus hyperplasia (29.4% vs. 3.1%).
• The time from MG diagnosis to MC was significantly longer in seronegative patients (8.2 vs. 3.1 years).
• No significant differences were observed in mechanical ventilation duration, ICU length of stay, or in-hospital mortality between groups.

Conclusions:

• Myasthenic crisis in seronegative MG predominantly affects younger patients and occurs later in the disease course.
• Despite demographic and disease course differences, the efficacy of crisis management and patient outcomes are similar for seronegative and AChR-MG patients.
• These findings highlight the importance of considering seronegative MG in MC management protocols.